MarketPR
Del-desiran trial results disappointed investors on Tuesday, sending Novartis (NVS) shares down more than 10% and marking the company's third clinical setback in a single week.
Three misses compressed into that window carry their own signal beyond any individual dataset. One trial failure registers as project-level risk.
Three in quick succession shifts the market's attention to a broader question: what the pipeline can offer as a counterweight, and how soon.
Del-desiran is the latest entry in that sequence, and the tape has now had three consecutive data points to price.
Keep reading